Abstract:LBA12082 Background: Chronic cough is a distressing symptom that detracts from the quality of life (QoL) of patients with cancer. Developing effective therapies for cough is an unmet need, with no approved medicines available. Neuromodulators like pregabalin may act centrally as cough suppressants. Methods: Randomized double-blind placebo-controlled study in the Department of Medical Oncology at Tata Memorial Hospital (Mumbai, India) in patients with locally advanced/metastatic non-small-cell lung cancer (NSCLC) with at least 2 weeks history of moderate or severe cough. Patients had ECOG PS 0-2, and creatinine clearance > 60 mL/min. Randomization was 1:1 to pregabalin 300 mg orally daily or matching placebo, both administered for 9 weeks. Primary endpoint was the difference in cough severity as measured by Visual Analog Scale (VAS) after 9 weeks treatment with pregabalin versus placebo. Secondary endpoints included cough severity on day 7 and week 9 measured by VAS, and Manchester Cough in Lung Cancer Scale (MCLCS); side-effects, and QoL assessed by EORTC QLQ C30 and LC13. Means of the change from baseline scores were calculated for patients in each arm, and compared between two arms by independent samples Mann Whitney U test. P 3 toxicities between the two arms; P=0.908. Systemic cancer-directed therapy was started in 95.2% and 91.4% of patients in the pregabalin and placebo arms, respectively; P=0.328. By week 9, subjective improvement in cough was reported by 45 (57%) patients in pregabalin arm, and 40 (52.6%) patients in placebo arm; P=0.846. The mean VAS score (in mm) decreased from 71.58 at baseline, to 45.32 at day 7, and 19.73 by week 9 in the pregabalin arm; corresponding values in the placebo arm were 71.74, 46.23, and 21.18, respectively; P=0.530. Cough assessment by mean MCLCS scores showed a similar decrease throughout the course of the study, with no statistically significant differences between the two arms (Pregabalin-Baseline: 27.63, Day 7: 23.49, Week 9: 17.39; Placebo-Baseline: 27.28, Day 7: 23, Week 9: 17.34); P=0.455. There was no significant difference in QoL between the two arms. Mean LCCO (cough symptom question on QLQ LC13) score decreased from 75.9 (baseline) to 54.2 (day 7) to 36.4 (week 9) in pregabalin arm, vs 66.3, 54, and 31.4, respectively, in placebo arm; P=0.150. Conclusions: Pregabalin does not lead to a significant decrease in cough in patients with lung cancer. Systemic cancer-directed therapy is the most effective antitussive therapy for cancer-induced cough. Clinical trial information: CTRI/2020/11/029275 .

A randomized, double-blinded, placebo-controlled clinical trial of duloxetine hydrochloride enteric-coated tablets in the treatment of refractory chronic cough

Clinical study of duloxetine in treatment of persistent somatoform pain disorder

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial of Qi-Zhi-Wei-Tong Granules on Postprandial Distress Syndrome-Predominant Functional Dyspepsia

New Strategy for Cough Treatment-Comparison Effect and Safety of Cofetol Cough Syrup with Dextromethorphan Hydrobromide, Chorpheniramine Mateate and Pseudoe Phedrine Hydiochloride Solution in the Treatment of Acute Cough

Decoding the impact of the placebo response in clinical trials for chronic cough

Flupentixol/melitracen for chronic refractory cough after treatment failure with other neuromodulators

Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough

Cough Reflex Hypersensitivity as a Key Treatable Trait

Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough

Management of non-pharmacologic therapy for chronic refractory cough: Mechanism, composition, applicable population, and assessment

Future Directions in Chronic Cough

Translating Cough Mechanisms Into Better Cough Suppressants

Cough hypersensitivity and chronic cough

Randomized double-blind placebo-controlled trial evaluating pregabalin for chronic cough in patients with lung cancer.

Multi-center,randomized,and double-blind controlled clinical trial of duloxetine enteric capsule in treatment of depression

Pregabalin for chronic cough due to lung cancer: randomized, double-blind, placebo-controlled trial

From bench to bedside: The role of cough hypersensitivity in chronic cough

Multidisciplinary Team Discussion Based on Etiological Treatment Improves Refractory Chronic Cough Outcomes

Characterization of Codeine Treatment Responders Among Patients with Refractory or Unexplained Chronic Cough: A Prospective Real-World Cohort Study

Psychological morbidity and chronic cough: which is predominant? A comparison of clinical characteristics

Effectiveness and safety of Xingbei Zhike granules in patients with postinfectious cough: A multicenter, randomized, double-blinded, placebo-controlled trial